1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market. The stock is down by 74% over the trailing-12-month period and, at under $4 per share, is barely above its 52-week low. Still, Wall Street analysts are bullish on Iovance. Their lowest price target is $6, the highest is $32, and the average is $19.54, according to Yahoo! Finance. Do Iovance's prospects justify these projections? Here's what investors need to know about this small-cap biotech company. Iovance Biotherapeutics develops therapies that harness the power of tumor-infiltrating lymphocytes (TILs), immune cells that can target and destroy cancer cells. Iovance's TIL-based treatments are made from the patient's cells through a proprietary procedure. The company's Amtagvi, a medicine for melanoma that earned approval from the U.S. Food and Drug Administration (FDA) last year, takes 34 days to manufacture. Amtagvi be
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 11/6/25 - Beat
IOVA
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IOVA's page on the SEC website